Plutux
$0.95
-5.23%
2026-09-04 10:51:54 EDT-$0.05
Healthcare
Biotechnology
NASDAQ
Active Trading

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements ...

Price Action

$0.95
-5.23%-$0.05
High
Low
52W High-72.1%
Rel. vol
Interval
Range43m
VolumeSMA5SMA10
ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company headquartered in Fremont, California. The company is dedicated to developing innovative therapies for critical healthcare needs, primarily in oncology/hematology and central nervous system (CNS) disorders. Its pipeline includes six drug candidates and one medical device: ABV-1501 for triple-negative breast cancer ...ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company headquartered in Fremont, California. The company is dedicated to developing innovative therapies for critical healthcare needs, primarily in oncology/hematology and central nervous system (CNS) disorders. Its pipeline includes six drug candidates and one medical device: ABV-1501 for triple-negative breast cancer (Phase I/II), ABV-1504 for major depressive disorder (Phase II completed), ABV-1505 for ADHD (Phase II), ABV-1703 for pancreatic cancer (Phase I completed), ABV-1702 for myelodysplastic syndromes (Phase I completed), ABV-1601 for depression in cancer patients (Phase I/II), and ABV-1701 (Vitargus) for retinal detachment or vitreous hemorrhage. The company collaborates with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation, and operates as a subsidiary of YuanGene Corporation. Financially, ABVC has a market cap of approximately $25 million, with minimal revenue and ongoing losses typical of clinical-stage biotech firms. As of the latest data, it employs about 30 people. The company was incorporated in Nevada in 2002, though some sources suggest a founding year of 1990. ABVC has announced plans for a spin-off of BioKey, indicating strategic restructuring. Despite financial challenges, ABVC continues to advance its clinical programs and forge partnerships, aiming to bring its therapies to market.
Founded
2002
Employees
18
CEO
Uttam Yashwant Patil
Full Name
ABVC BioPharma, Inc.
Sector
Healthcare
Industry
Biotechnology
ROE
-71.47%
Market Cap
$0.03B
Current Ratio
0.07
WACC
7.65%
ROIC
-88.68%

Contact Information

510 668 0881
44370 Old Warm Springs Boulevard, Fremont, CA 94538

Related stocksBiotechnology

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026